Ligand Pharmaceuticals Inc. filings document the regulatory record for a Nasdaq-listed biopharmaceutical royalty aggregator with common stock trading under LGND. The company’s disclosures cover royalty portfolio economics, technology licenses, partner-product clinical and regulatory matters, operating results, milestone payments, commercial royalties, Captisol® material sales, and NITRICIL™ licensing.
Ligand’s SEC record also includes Form 8-K reports on material agreements, license-program rights, credit-agreement amendments, Regulation FD communications, capital-structure disclosures, and financial results. Proxy materials describe board matters, shareholder voting items, executive compensation, equity awards, and governance practices for the public company.
Ligand Pharmaceuticals (LGND) reported stronger results in the quarter ended June 30, 2025, with total revenues of $47.6 million, up from $41.5 million a year earlier, driven by higher royalties of $36.4 million and a jump in income from financial royalty assets to $6.3 million from $0.6 million. Operating income for the quarter turned positive at $8.4 million compared with an operating loss a year earlier, reflecting higher royalty receipts and Captisol sales.
Despite the quarterly improvement, the first half of 2025 produced a $51.9 million net loss versus net income of $34.2 million in the prior-year period, largely reflecting non-operating swings and a $44.3 million one-time research and development expense tied to the Castle Creek transaction. Material transactions this period include the Castle Creek investment (Ligand funded $50 million of a $75 million syndicate, allocating $44.3 million to D-Fi royalty rights and $5.8 million to a warrant) and the prior Apeiron acquisition (base consideration $100.5 million with Qarziba royalty assets added). Balance sheet highlights: total assets $948.6 million, cash $67.7 million, and stockholders' equity $828.5 million; Pelthos was classified as held for sale with assets of $35.2 million and related liabilities of $35.7 million.
Ligand Pharmaceuticals (LGND) – Form 4 filing: Chief Financial Officer Octavio Espinoza acquired 224 common shares on 30 June 2025 through the company’s Employee Stock Purchase Plan (ESPP), a transaction coded “J,” which is exempt under Rules 16b-3(c) and 16b-3(d).
The shares were purchased at an average price of $91.08 per share, increasing Espinoza’s direct beneficial ownership to 29,852 shares. No derivative securities were reported in Table II. The filing was signed on 2 July 2025 by an attorney-in-fact on behalf of the executive.
Because the purchase occurred under an automatic ESPP rather than an open-market discretionary trade, the signal for insider sentiment is modest; however, it still marginally aligns executive and shareholder interests.
Form 3/A filing for Ligand Pharmaceuticals Inc. (LGND) discloses an amended initial beneficial ownership statement for Chief Financial Officer Octavio Espinoza.
- Date of event: 11/01/2022 (original Form 3 date); amendment filed 07/02/2025.
- Shares owned: 1,696 shares of LGND common stock reported as directly held.
- Purpose of amendment: Corrects the original Form 3, which inadvertently understated Mr. Espinoza’s direct holdings by exactly 1,696 shares. The correction also updates related Form 4 reports filed through the amendment date.
- Reporting person’s role: Officer – Chief Financial Officer.
No derivative securities are reported, and there are no other changes to ownership structure, relationships, or control disclosed in this filing.